Balchem’s Breakthrough Nutrient Formula Shows Superior Absorption in Clinical Trials
Published on 11/04/2025 at 17:52 | Redaktion boerse-global.de
Shares of Balchem Corporation demonstrated minimal movement in recent trading, holding steady despite the release of groundbreaking clinical data for its specialized nutrient compound Optifolin+®. The market’s muted response contrasts with significant scientific validation revealing substantially enhanced bioavailability compared to conventional alternatives.
Recently published research in the peer-reviewed journal Food & Nutrition Research demonstrates that Balchem’s Optifolin+® achieves bioavailability 2.6 times greater than standard folic acid formulations. The randomized double-blind study further documented absorption rates 3.5 times faster than conventional options. Participants receiving the specialized compound reached peak plasma concentration in under 60 minutes, dramatically outpacing the 2.8 hours required by standard folic acid.
Beyond absorption metrics, the investigation Read more...
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
